Alluvi, previously known as LY3414901, represents a significant advancement in obesity management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) https://alluvi-healthcare223966.greenviewblog.com/662476/alluvi-a-deep-dive-into-the-drug-s-possibility